Bank Of America Corp Morpho Sys Ag Transaction History

Bank Of America Corp

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$17.36 - $19.34 $389,020 - $433,390	-22,409 Reduced 86.82%	3,401 $61,000
Q1 2024 May 15, 2024	BUY	$8.6 - $18.18 $173,823 - $367,454	20,212 Added 361.06%	25,810 $468,000
Q4 2023 Feb 14, 2024	BUY	$4.55 - $9.9 $5,305 - $11,543	1,166 Added 26.31%	5,598 $55,000
Q2 2023 Aug 14, 2023	BUY	$3.95 - $7.74 $7,702 - $15,093	1,950 Added 78.57%	4,432 $33,000
Q1 2023 May 12, 2023	BUY	$3.56 - $5.22 $566 - $829	159 Added 6.84%	2,482 $9,000
Q4 2022 Feb 10, 2023	SELL	$3.21 - $5.74 $25,224 - $45,104	-7,858 Reduced 77.18%	2,323 $8,000
Q3 2022 Nov 14, 2022	SELL	$4.14 - $22.13 $5,688 - $30,406	-1,374 Reduced 11.89%	10,181 $52,000
Q2 2022 Aug 12, 2022	BUY	$4.51 - $7.39 $694 - $1,138	154 Added 1.35%	11,555 $55,000
Q1 2022 May 16, 2022	SELL	$5.87 - $9.73 $6,944 - $11,510	-1,183 Reduced 9.4%	11,401 $77,000
Q4 2021 Feb 08, 2022	SELL	$9.08 - $12.45 $228,579 - $313,416	-25,174 Reduced 66.67%	12,584 $119,000
Q3 2021 Nov 15, 2021	BUY	$11.76 - $19.51 $302,749 - $502,265	25,744 Added 214.28%	37,758 $444,000
Q2 2021 Sep 13, 2021	BUY	$18.95 - $23.95 $227,665 - $287,735	12,014 New	12,014 $231,000

1.8M

14.7K

Ticker MOR
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 136,614,000
Description
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, f...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.